

**Embargoed until 12 noon (Eastern Standard Time) / 6 pm (Central European Time, Thursday, 17 November 2016)**

Thursday, 17 November 2016

## **EU-FP7 project BLUEPRINT celebrates major manuscript release**

*BLUEPRINT scientists release a collection of 26 publications in Cell, Cell Press-associated and other high-impact journals. These are part of a package of 41 publications by the International Human Epigenome Consortium (IHEC) of which BLUEPRINT is a member.*

One of the great mysteries in biology is how the many different cell types that make up our bodies are derived from a single cell and from one DNA sequence, or genome. We have learned a lot from studying the human genome, but have only partially unveiled the processes underlying cell determination. The identity of each cell type is largely defined by an instructive layer of molecular annotations on top of the genome – the epigenome – which acts as a blueprint unique to each cell type and developmental stage. Unlike the genome the epigenome changes as cells develop and in response to changes in the environment. Defects in the factors that read, write and erase the epigenetic blueprint are involved in many diseases. The comprehensive analysis of the epigenomes of healthy and abnormal cells will facilitate new ways to diagnose and treat various diseases, and ultimately lead to improved health outcomes.

A collection of 41 coordinated papers now published by scientists from across the International Human Epigenome Consortium (IHEC) sheds light on these processes, taking global research in the field of epigenomics a major step forward. A set of 24 manuscripts has been released as a package in *Cell* and *Cell Press*-associated journals, and an additional 17 papers have been published in other high-impact journals.

These papers represent the most recent work of IHEC member projects from Canada, the European Union, Germany, Japan, Singapore, South Korea, and the United States. The collection of publications showcases the achievements and scientific progress made by IHEC in core areas of current epigenetic investigations.

“The collection of manuscripts impressively demonstrates how epigenetic information and analyses can help find answers to pressing questions related to the cellular mechanisms associated with complex human diseases”, said Professor Hendrik (Henk) Stunnenberg from Radboud University, The Netherlands, former Chair of the IHEC International Scientific Steering Committee and coordinator of the EU-funded BLUEPRINT project.

### **In a Nutshell: Key Findings from the Collection of Papers**

Key research findings presented in the collection can be collated into four broad categories with a *first* group of papers presenting a series of molecular and computational approaches to deconvolute distinct epigenomic signatures from tissues that contain a mix of different cell types.

A *second* group of publications highlights BLUEPRINT’s significant efforts and investments to develop new computational tools for the access, distribution and sharing of epigenomic data via various channels to the community, thus upholding the European Commission’s pledge to maximise open access to its funded research.

In a *third* category, datasets produced by BLUEPRINT members were used to investigate molecular mechanisms underlying different cellular processes in normal and abnormal cell development. These analyses may in future help doctors to target the right treatments to the right patients.

A *fourth* group of papers in the collection uses epigenomic information to characterize how nuclear organization and genetic variants affect the expression of genes, and how these genes in turn contribute to disease.

“BLUEPRINT has produced more new science and more understanding of blood cell disease than we could have imagined at the outset,” “We have made the data of >1000 datasets publicly available” says Henk Stunnenberg. “Moreover, we have forged an alliance of researchers and innovative companies from around Europe and, working closely with international partners, we already see results that, in time, will improve the lives of patients.”

## Reference

The full collection of IHEC papers is available at: <http://www.cell.com/consortium/IHEC>

###

## Notes to Editors

### About BLUEPRINT

The project BLUEPRINT – A BLUEPRINT of Haematopoietic Epigenomes is a large-scale research project receiving close to 30 million euro funding from the EU. 42 leading European universities, research institutes and industry entrepreneurs participate in what is one of the two first so-called high impact research initiatives to receive funding from the EU. For more information, please visit:

<http://www.blueprint-epigenome.eu>

### BLUEPRINT Partners

The BLUEPRINT consortium consists of 42 partner organisations, representing 33 academic groups and 9 companies (mostly Small and Medium Enterprises (SMEs)) from 12 countries. For more information on partner organisations, Principle Investigators, Scientific Advisory Board and Associate members, please visit:

<http://www.blueprint-epigenome.eu/index.cfm?p=D241B438-AF5E-72CF-9CAA252FE3C0B67F>

### Access to BLUEPRINT Data

BLUEPRINT and the International Human Epigenome Consortium (IHEC) make available comprehensive sets of reference epigenomes relevant to health and disease. The [IHEC Data Portal](#) can be used to view, search and download the data released by the different IHEC-associated projects. In addition, the BLUEPRINT data is accessible via:

[BLUEPRINT DCC](#)

[BLUEPRINT Data Analysis Portal](#)

[Genomatix](#)

Trackhubs ([Ensembl](#) or [USCS](#))

### **About IHEC**

The International Human Epigenome Consortium (IHEC) is a global consortium with the primary goal of providing free access to high-resolution reference human epigenome maps for normal and disease cell types to the research community. IHEC members support related projects to improve epigenomic technologies, investigate epigenetic regulation in disease processes, and explore broader gene-environment interactions in human health. Current full members of IHEC include: AMED-CREST/IHEC Team Japan; DLR-PT for BMBF German Epigenome Programme DEEP; CIHR Canadian Epigenetics Environment, and Health Research Consortium (CEEHRC); European Union FP7 BLUEPRINT Project; Hong Kong Epigenomics Project; KNIH Korea Epigenome Project; the NIH/NHGRI ENCODE Project; the NIH Roadmap Epigenomics Program; and the Singapore Epigenome Project.

For more information, please visit: <http://ihec-epigenomes.org/>

### **Contact Information**

#### **For BLUEPRINT**

Prof.dr. Hendrik G. Stunnenberg, Coordinator of BLUEPRINT  
Department of Molecular Biology  
Radboud University, Nijmegen, The Netherlands  
Email: [h.stunnenberg@ncmls.ru.nl](mailto:h.stunnenberg@ncmls.ru.nl)  
Phone +31 24 3610524

#### **For IHEC**

##### **IHEC Executive Committee**

Eric Marcotte, PhD  
Chair, IHEC Executive Committee  
Canadian Institutes of Health Research  
Email: [eric.marcotte@cihr-irsc.gc.ca](mailto:eric.marcotte@cihr-irsc.gc.ca)

##### **IHEC International Scientific Steering Committee**

Martin Hirst, PhD  
Chair, IHEC International Scientific Steering Committee  
Associate Professor, Department of Microbiology and Immunology  
University of British Columbia  
Email: [hirstm@mail.ubc.ca](mailto:hirstm@mail.ubc.ca)

##### **IHEC Communications**

Stephanie Weber  
European Research and Project Office  
Head of Communications & Marketing  
Email: [s.weber@eurice.eu](mailto:s.weber@eurice.eu)